Search for a doctor

Vamsi Velcheti, M.D.

  1. Oncologist
Request an Appointment

Departments

Location

  1. Jacksonville, Florida

Languages

EnglishHindi

Existing patients

Vamsi Velcheti, M.D., M.B.A., F.A.S.C.O., F.C.C.P., serves as Chief of Hematology and Oncology and Florida Department of Health Chair of Cancer Research at Mayo Clinic. A nationally recognized expert in lung cancer, Dr. Velcheti has been instrumental in the development of novel therapeutics and serves on national and international scientific and educational committees, including at the American Society of Clinical Oncology (ASCO) and the International Association for the Study of Lung Cancer (IASLC). He has received numerous national awards and was named one of the Top Lung Cancer Doctors in the NYC area by Castle Connolly for four consecutive years (2021 — 2024). Holding an advanced degree in healthcare strategy, innovation, and entrepreneurship, he is at the forefront of deploying advanced AI and automation tools to transform cancer care delivery.

Dr. Velcheti leads a multidisciplinary thoracic oncology program specializing in biomarker-driven targeted therapies, immuno-oncology, and early-phase drug development. In addition, his pioneering work integrates AI-driven predictive models and automated care pathways to enhance diagnostic accuracy, streamline treatment planning, and deliver a more personalized and seamless patient experience, ultimately improving outcomes across the cancer care continuum.

  1. Lung cancer
  1. Chemotherapy
  2. Immunotherapy
  3. Targeted drug therapy
  • Thoracic Oncology: Specializing in the diagnosis and treatment of non-small cell and small cell lung cancers, with a focus on precision medicine and biomarker-driven therapies
  • Immuno-Oncology: Expertise in immune checkpoint inhibitors, neoadjuvant and perioperative immunotherapy strategies, and combination approaches to enhance immune response.
  • Targeted Therapies: Development and clinical application of novel therapeutics for oncogene-driven lung cancers, including EGFR, ALK, KRAS, MET, ROS1, RET, and NTRK alterations. Identifying and treating rare fusion-positive lung cancers using next-generation inhibitors, investigating resistance mechanisms, and leading clinical trials for these molecular subtypes.
  • Early-Phase Drug Development: Leadership in first-in-human and early-phase clinical trials, advancing innovative therapies for thoracic malignancies and rare oncogene-driven cancers.
  • Artificial Intelligence and Automation in Oncology: Integrating AI-driven predictive models, radiomics, and automated care pathways to improve diagnostic accuracy, streamline treatment planning, enhance patient navigation, and elevate overall patient experience and outcomes.
  • Multidisciplinary Cancer Care: Building and leading collaborative teams that include medical, surgical, and radiation oncology to deliver coordinated, personalized treatment plans.
  • Patient-Centered Outcomes: Focused on improving quality of life, survivorship, and patient satisfaction through technology-enabled care delivery models and innovative approaches.
  1. 2023
    MBA - Health Care Strategy/ EntrepreneurshipNew York University
  2. 2013
    CertificateClinical Research Program, Yale University
  3. 2013
    Fellowship - Hematology & OncologyYale University
  4. 2010
    Residency - Internal MedicineOchsner Medical Center
  5. 2007
    Post Doctoral Researcher and Research AssociateDepartment of Medical Oncology, Washington University School of Medicine
  6. 2005
    Internship - Medicine-TransitionalKing Edward Memorial Hospital
  7. 2004
    MDArmed Forces Medical College

Awards and honors

  1. 2019
    Leadership Development ProgramAmerican Society of Clinical Oncology
  2. 2015
    Initiative Research AwardScott Hamilton CARES Foundation
  3. 2015
    Career Development AwardAmerican Society of Clinical Oncology
  4. 2013
    Outstanding Cancer Research AwardHematology-Oncology Program, Yale Cancer Center
  5. 2012
    Merit AwardAmerican Society of Clinical Oncology
  6. 2012
    Young Investigator workshop training AwardEuropean Organisation for Research and Treatment of Cancer, National Cancer Information
  7. 2012
    Young Investigator AwardAmerican Society of Clinical Oncology
  8. 2010
    Edward D. Frohlich, MD, Research AwardOchsner Clinic Foundation Hospital, New Orleans, LA
  9. 2010
    Researcher of the YearInternal Medicine Program, Ochsner Clinic Foundation Hospital, New Orleans, LA
  10. 2008
    Travel Scholarship AwardAmerican Society of Hematology
  11. 2002
    College Blues AwardStudent Scientific Society, Armed Forces Medical College, Maharashtra University of Health Sciences
  12. 2000
    Summer Research Fellowship AwardIndian Council for Medical Research, New Delhi, India

Professional memberships

  1. 2023 - 2026
    MemberMultidisciplinary Clinical Science Committee, International Association for the Study of Lung Cancer
  2. 2022 - 2023
    MemberScientific Program Committee, American Society of Clinical Oncology
  3. 2020 - 2025
    MemberData Safety and Monitoring Committee, New York University Comprehensive Cancer Center
  4. 2020 - 2023
    MemberScientific Program Committee, American Society of Clinical Oncology
  5. 2019 - present
    MemberAdvisory Panel, American Society of Clinical Oncology
  6. 2018 - 2023
    MemberContinuing Education Committee, International Association for the Study of Lung Cancer
  7. 2018 - 2019
    MemberProtocol Review and Monitoring Committee, New York University Comprehensive Cancer Center
  8. 2018
    FellowAmerican College of Chest Physicians
  9. 2018 - present
    MemberContinuing Medical Education Committee, International Association of Study of Lung Cancer
  10. 2017 - 2019
    MemberAbstract Review Committee, National Comprehensive Cancer Network
  11. 2017 - 2018
    MemberAPEX Council, Cleveland Clinic
  12. 2017 - 2018
    Panel MemberManagement of lmmunotherapy-Related Adverse Events Panel, National Comprehensive Cancer Center Network
  13. 2017 - 2018
    MemberScientific Advisory Council, Immunotherapy Collaborative of Networked Communities
  14. 2017 - 2018
    Track LeaderCancer Education Committee, American Society of Clinical Oncology
  15. 2017
    FellowAmerican College of Physicians
  16. 2017 - present
    MemberThoracic Oncology Working Group, Hoosier Cancer Research Network
  17. 2016 - 2018
    MemberTen Years' Time Chest Disease Committee, Cleveland Clinic
  18. 2016 - 2018
    MemberLung Cancer Tissue Utilization, Cleveland Clinic
  19. 2016 - 2018
    MemberResearch Program RFP Development Committee, National Comprehensive Cancer Network
  20. 2016
    Peer ReviewerLung Cancer Research Program, United States Department of Defense
  21. 2016 - present
    MemberCytokine Working Group, National Cancer Institute
  22. 2015 - 2018
    MemberCancer Education Committee, American Society of Clinical Oncology
  23. 2013 - 2018
    MemberDevelopmental Therapeutics Program, Case Comprehensive Cancer Center
  24. 2013 - 2018
    MemberInternational Thymic Malignancies Interest Group, Research Committee, International Association for the Study of Lung Cancer
  25. 2013 - 2014
    MemberProtocol Review and Monitoring Committee, Case Comprehensive Cancer Center
  26. 2012 - 2013
    MemberGraduate Medical Education Committee, Yale New Haven Hospital

Publications